Where Sensitivity Becomes Outcomes
More cfDNA is not just a technical achievement. It unlocks clinical applications that are currently out of reach.
Minimal Residual Disease (MRD)
While a patient is undergoing cancer treatment, the critical question is whether any tumor cells remain. MRD monitoring uses cfDNA to detect residual disease before it becomes clinically visible, enabling earlier intervention and more personalized follow-up.
The challenge is that post-treatment tumor-derived cfDNA fractions can be extraordinarily low, sometimes one mutant molecule per million. Current liquid biopsy approaches are limited by the small cfDNA inputs from a standard blood draw. Plasma-Sieve removes that ceiling.
Multi-Cancer Early Detection (MCED)
MCED tests aim to detect cancer signals across multiple tumor types from a single blood sample. The most clinically meaningful window for detection is early stage, when tumor-derived cfDNA fractions are lowest and cure rates are highest.
This is precisely where standard blood draw volumes fall short. By providing dramatically more cfDNA input, Plasma-Sieve enables MCED tests to operate with statistical confidence at the early-stage signal levels that matter most.
The Case for Earlier Detection
>90%
5-year survival rate for many cancers detected at Stage I
<20%
5-year survival rate for the same cancers detected at Stage IV
70%
of cancer deaths occur in cancers with no current recommended screening test
Statistics are representative estimates drawn from published epidemiological literature. This technology is investigational and not FDA-cleared.
A Platform, Not a Single Test
Plasma-Sieve is not tied to a single assay or cancer type. The increased cfDNA yield it produces is compatible with any downstream analytical platform: next-generation sequencing panels, digital PCR, methylation profiling, and emerging single-molecule detection technologies.
This makes it an upstream enabler for the entire liquid biopsy market (~ $2B annually), improving the sensitivity of any test that depends on cfDNA input quantity.
Key Outcome
A new floor for liquid biopsy sensitivity in both MRD monitoring and MCED screening: every cfDNA fragment counts, and Plasma-Sieve captures more of them.